Wells Fargo analyst Stan Berenshteyn upgraded Omnicell (OMCL) to Overweight from Equal Weight with a price target of $35, up from $31. The company faces bookings and tariff pressures, but 2025 may be a “max pain” year as trade deals and strengthening robot demand could be positive catalysts for 2026, the analyst tells investors in a research note. As such, the firm sees an attractive risk/reward at current share levels. Wells says its Q2 survey shows robotics demand looks to be improving sequentially through at least 2027. While 2025 bookings may remain challenged, there are prospects for improving demand in 2026 to balance near-term risks, contends the firm.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMCL:
- Positive Outlook for Omnicell: Strong Demand and Market Stability Drive Buy Rating
- Omnicell upgraded to Overweight from Equal Weight at Wells Fargo
- Omnicell price target lowered to $53 from $64 at Craig-Hallum
- Omnicell price target lowered to $30 from $37 at BofA
- Omnicell price target lowered to $40 from $62 at Benchmark